53929-59-2

Usage

Uses

Used in Chemical Synthesis:
4-Methyl-Pyridine-2,3-Diamine is used as a key intermediate in the synthesis of various chemical compounds. Its unique structure allows for versatile reactivity, making it a valuable component in the production of a wide range of chemicals.
Used in Pharmaceutical Industry:
4-Methyl-Pyridine-2,3-Diamine is used as a building block for the development of pharmaceuticals. Its presence in the molecular structure can influence the properties and effectiveness of the resulting drug molecules, contributing to the advancement of new therapeutic agents.
Used in Research and Development:
4-Methyl-Pyridine-2,3-Diamine is used as a research compound in academic and industrial laboratories. Its reactivity and bonding patterns are of interest to scientists studying chemical reactions and exploring new synthetic pathways.
Used in Material Science:
4-Methyl-Pyridine-2,3-Diamine is used as a component in the development of new materials with specific properties. Its incorporation into material structures can influence their physical and chemical characteristics, such as conductivity, stability, or reactivity.

InChI:InChI=1/C6H9N3/c1-4-2-3-9-6(8)5(4)7/h2-3H,7H2,1H3,(H2,8,9)

Upstream product

• 6635-86-5 2-amino-4-methyl-3-nitropyridine 
• 100114-04-3 3-Amino-4-methyl-pyridin-1-oxid 
• 1038919-62-8 4-methyl-2-nitropyridin-3-amine 

Downstream Products

• 115951-60-5 2,7-Dimethylimidazo<4,5-b>pyridine 
• 115951-70-7 2-Methyl-3H-imidazo[4,5-b]pyridine-7-carboxylic acid [1-(4-hydroxy-3-methoxy-phenyl)-meth-(E)-ylidene]-hydrazide 
• 115951-69-4 2-Methyl-3H-imidazo[4,5-b]pyridine-7-carboxylic acid [1-(3,4-dimethoxy-phenyl)-meth-(E)-ylidene]-hydrazide 
• 133240-38-7 L 158338 
• 577777-13-0 [7-methyl-2-(3H-imidazo[4,5-b]pyridine)-2-yl]acetonitrile 
• 133240-16-1 2-Isopropyl-7-methylimidazo[4,5-b]pyridine 
• 944746-01-4 2-(2,4-difluorophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 
• 845960-13-6 2-(4-fluorophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 
• 78316-08-2 7-Imidazo<4,5-b>pyridine carboxylic acid 
• 1274481-63-8 C₁₄H₁₃N₃O 
• 1274808-28-4 C₁₃H₁₀ClN₃ 
• 1367866-23-6 2-(4-methoxyphenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 
• 944745-89-5 2-(4-chlorophenyl)-7-methyl-3H-imidazo[4,5-b]pyridine 

Relevant academic research and scientific papers

Imidazopyridine- and purine-thioacetamide derivatives: Potent inhibitors of nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1)

Nucleotide pyrophosphatase/phosphodiesterase 1 (NPP1) belongs to the family of ecto-nucleotidases, which control extracellular nucleotide, nucleoside, and (di)phosphate levels. To study the (patho)physiological roles of NPP1 potent and selective inhibitors with drug-like properties are required. Therefore, a compound library was screened for NPP1 inhibitors using a colorimetric assay with p-nitrophenyl 5′-thymidine monophosphate (p-Nph-5′-TMP) as an artificial substrate. This led to the discovery of 2-(3H-imidazo[4,5-b]pyridin-2-ylthio)-N-(3,4-dimethoxyphenyl)acetamide (5a) as a hit compound with a Ki value of 217 nM. Subsequent structure-activity relationship studies led to the development of purine and imidazo[4,5-b]pyridine analogues with high inhibitory potency (Ki values of 5.00 nM and 29.6 nM, respectively) when assayed with p-Nph-5′-TMP as a substrate. Surprisingly, the compounds were significantly less potent when tested versus ATP as a substrate, with Ki values in the low micromolar range. A prototypic inhibitor was investigated for its mechanism of inhibition and found to be competitive versus both substrates.

2-(HETERO)ARYL-BENZIMIDAZOLE AND IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF ASPARAGIME EMETHYL TRANSFERASE

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR4; A2 is selected from:, a C5 heteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are β to one another; L1 is selected from: (i)A1-O-CH2-A2; (ii)A1-CH2-O-A2; (iii)A1-C(=O)-NH-A2; (iv)A1-CH(OH)-A2; (v)A1-CH2-NH-C(=O)-A2; (vi) A1-S-CH2-A2; (vii)A1- CH2-S-A2; (viii)A1-CH2-A2; and (ix)A1-CH(CH3)-O-A2; A1 is phenyl, optionally substituted by F or CF3; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies.

Design, synthesis and biological evaluation of novel imidazopyridines as potential antidiabetic GSK3β inhibitors

Design, synthesis and biological evaluation of the imidazopyridine analogs as novel GSK3β inhibitors for treatment of type 2 diabetes mellitus are described. Most of the analogs exhibited excellent inhibitory activities (IC50 44 nM) against glycogen synthase kinase 3β (GSK3β). The structure-activity relationship (SAR) of the imidazopyridine analogs and the binding mode of analog 23 in the catalytic domain of GSK3β, based on our X-ray crystallography study, are described. In particular, analog 28, which was selected as a potential drug candidate for treatment of type 2 diabetes mellitus, exhibited excellent GSK3β inhibition, pharmacokinetic profiles and blood glucose lowering effect in mouse.

AZABENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS

Provided herein are novel sirtuin-modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for e

COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARY ACTIVATING ACTIVITIES

Compounds of following formula (I) are provided that have both angiontensin Il receptor antagonist activity and PPARy agonist activity. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment of diseases with the co

IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The inventive imidazopyridine derivative can be used in a pharmaceutical composition for preventing or treating diseases such as diabetes, obesity, dementia, cancer, and inflammation, since it can efficiently inhibit the activities of several protein kina

PREVENTIVE AND/OR THERAPEUTIC AGENT FOR NEUTROPHILIC INFLAMMATION DISEASE

The present invention provides a preventive and/or therapeutic agent for neutrophilic inflammatory diseases which comprises, as an active ingredient, a bicyclic heterocyclic compound represented by formula (I): [wherein R 1 represents a hydrogen atom, substituted or unsubstituted alkyl, or the like, A 1 -A 2 -A 3 -A 4 represents N=CR 3 -CR 4 =CR 5 (wherein R 3 , R 4 , and R 5 are the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, and the like), Q represents substituted or unsubstituted phenylene, and the like, and T represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aroyl, and the like].

2-OXO-1-PYRROLIDINE DERIVATIVES

The present invention concerns 2-oxo-1 -pyrrolidine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

FUSED HETEROCYCLIC DERIVATIVES AS PPAR MODULATORS

The present invention is directed to compounds represented by the following structural formula, Formula I: wherein (a) X is selected from the group consisting of a single bond, O, S. S(O)2 and N; (b) U is an aliphatic linker; (c) Y is selected from the group consisting of C, O, S, NH and a single bond; (d) E is C(R3) (R4)A or A and wherein (i) A is selected from the group consisting of carboxyl, tetrazole, C1-C6 alkylnitrile, carboxamidek, sulfonamide and acylsulfonamide; (e) B is selected from the group consisting of S, O, C, and N; (f) Z is selected from the group consisting of N and C; with the proviso that when B is C then Z is N.

IMIDAZO(1,2-a)PYRIDINE DERIVATIVE

A compound reprsented by the following formula (I), its salts or nsolvates thereof capable of specifically or selectively expressig an antifungal activity in a broad spectrum based on the novel mechanism thereof of 1,6-β-glucan synthesis inhibition, and an antifungal agent containing any of them.